drugset / Trial / NCT01442987

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

NCT01442987

Phase 3 Completed 230 enrolled Hanmi Pharmaceutical Company Limited
RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.

Timeline

Start
2011-05
Primary completion
2013-04
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 40 mg Oral
Comparator Atorvastatin Small molecule 80 mg Oral
Subject Irbesartan Small molecule 300 mg Oral